Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Modulating autophagy for therapeutic benefit

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Carew, J. S.
  • Nawrocki, S. T.
  • Cleveland, John

publication date

  • September 2007

journal

  • Autophagy  Journal

abstract

  • Autophagy is an ancient cell survival pathway that allows cells to recoup ATP and essential building blocks for biosynthesis when they are starved of nutrients or when they are exposed to hypoxia, which are hallmarks of the tumor microenvironment. This pathway involves the formation of double-membraned vesicles, coined autophagosomes, which envelop bulk cellular material and/or organelles and that subsequently fuse with lysosomes that degrade their cargo. Autophagy has been suggested to play important roles in chemoresistance of cancer to some therapeutic agents, which typically induce an apoptotic response. For example, the histone deacetylase inhibitor SAHA induces both apoptosis and autophagy, suggesting that agents that disrupt the autophagy pathway might augment its efficacy as a therapeutic agent. We tested this notion in a model of Imatinib-refractory chronic myelogenous leukemia (CML) and in imatinib-resistant primary CML cells from patients bearing mutations in Bcr-Abl, including the T315I mutation that causes resistance to currently utilized tyrosine kinase inhibitors and translates into a very poor clinical prognosis. Agents that disrupt autophagy were shown to synergize with SAHA in provoking apoptotic death of these refractory tumors. These findings support the use of agents that disrupt the autophagy pathway in settings of chemorefractory malignancies.

subject areas

  • Adenine
  • Animals
  • Autophagy
  • Chloroquine
  • Drug Resistance, Neoplasm
  • Histone Deacetylase Inhibitors
  • Humans
  • Hydroxamic Acids
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Models, Biological
  • Neoplasms
scroll to property group menus

Research

keywords

  • Bcr-Abl
  • CML
  • SAHA
  • apoptosis
  • autophagy
  • lysosome
  • p53
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1554-8627

PubMed ID

  • 17495516
scroll to property group menus

Additional Document Info

start page

  • 464

end page

  • 467

volume

  • 3

issue

  • 5

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support